TWST · Nasdaq · CIK 0001581280

Twist Bioscience Corp

Twist Bioscience Corp’s most recent SEC filing in our snapshot is a Form 4 filed on Oct 27, 2026. In fiscal 2025 (year ended Sep 30, 2025) it reported revenue of $376.6M and net income of -$77.7M, according to its XBRL data on EDGAR. Its EDGAR record lists 150 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
$376.6M
Net income, FY2025
-$77.7M
Form 4 filings on record, past 12 months
150

Company overview

Legal name (as filed)
Twist Bioscience Corp
Ticker
TWST
SEC Central Index Key (CIK)
0001581280
Business address
SOUTH SAN FRANCISCO, CA
State or country of incorporation
DE
Fiscal year ends
September 30
SEC filer category
Large accelerated filer
Position in SEC ticker list
#975 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from Twist Bioscience Corp’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
$132.3MFY2021$203.6MFY2022$245.1MFY2023$313.0MFY2024$376.6MFY2025
Net income
-$152.1MFY2021-$217.9MFY2022-$204.6MFY2023-$208.7MFY2024-$77.7MFY2025
TWST annual results
ItemFY2021
ended Sep 30, 2021		FY2022
ended Sep 30, 2022		FY2023
ended Sep 30, 2023		FY2024
ended Sep 30, 2024		FY2025
ended Sep 30, 2025
Revenue$132.3M$203.6M$245.1M$313.0M$376.6M
Net income-$152.1M-$217.9M-$204.6M-$208.7M-$77.7M
Diluted EPS-$3.15-$4.04-$3.60-$3.60-$1.30
Total assets$702.1M$961.4M$776.4M$614.3M$641.9M
Cash and equivalents$465.8M$378.7M$286.5M$226.3M$183.0M

XBRL tags used: revenue = RevenueFromContractWithCustomerIncludingAssessedTax; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

TWST latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Nov 17, 202510-KAnnual report· period Sep 30, 2025Document · Index
Aug 3, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Aug 19, 20268-KRegulation FD disclosure· period Aug 18, 2026Document · Index
Jan 6, 2026DEF 14ADefinitive proxy statement· period Feb 5, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about Twist Bioscience Corp, by form type:

144 ×204 ×18SCHEDULE 13G/A ×2
TWST recent filings
FiledFormWhat it isOriginal
Oct 27, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 23, 2026Document · Index
Oct 23, 2026144Notice of proposed sale of securitiesDocument · Index
Oct 13, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 9, 2026Document · Index
Oct 9, 2026144Notice of proposed sale of securitiesDocument · Index
Oct 7, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 5, 2026Document · Index
Oct 5, 2026144Notice of proposed sale of securitiesDocument · Index
Oct 5, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 1, 2026Document · Index
Oct 5, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 2, 2026Document · Index
Oct 5, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 2, 2026Document · Index
Oct 5, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 2, 2026Document · Index
Oct 5, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 2, 2026Document · Index
Oct 5, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 2, 2026Document · Index
Oct 2, 2026144Notice of proposed sale of securitiesDocument · Index
Oct 2, 2026144Notice of proposed sale of securitiesDocument · Index
Oct 2, 2026144Notice of proposed sale of securitiesDocument · Index
Oct 2, 2026144Notice of proposed sale of securitiesDocument · Index
Oct 2, 2026144Notice of proposed sale of securitiesDocument · Index
Oct 2, 2026144Notice of proposed sale of securitiesDocument · Index
Oct 1, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 25, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 24, 2026Document · Index
Sep 24, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 23, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 21, 2026Document · Index
Sep 23, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 21, 2026Document · Index
Sep 23, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 21, 2026Document · Index
Sep 21, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 21, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 21, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 21, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 17, 2026Document · Index
Sep 17, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 17, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 10, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 8, 2026Document · Index
Sep 10, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 8, 2026Document · Index
Sep 10, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 8, 2026Document · Index
Sep 10, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 8, 2026Document · Index
Sep 8, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 8, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 8, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 8, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 8, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Sep 8, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index

Insider filing activity

150 Form 4 filings appear in Twist Bioscience Corp’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Biological Products, (No Diagnostic Substances)

All 61 companies in Biological Products, (No Diagnostic Substances)· Companies headquartered in California

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001581280 and XBRL company facts. Twist Bioscience Corp on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.